Stockscreener 앱 받기
36.91
7.19%
-2.86
전일 마감가:
$39.77
열려 있는:
$40.11
하루 거래량:
821.02K
Relative Volume:
0.89
시가총액:
$3.73B
수익:
-
순이익/손실:
$-804.34M
주가수익비율:
-3.9224
EPS:
-9.41
순현금흐름:
$-531.06M
1주 성능:
-10.91%
1개월 성능:
-5.43%
6개월 성능:
-10.61%
1년 성능:
-20.74%
1일 변동 폭
$36.82
$40.82
1주일 범위
$36.82
$42.33
52주 변동 폭
$26.80
$62.21
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
36.91 | 3.73B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
(BHVN) Technical Pivots with Risk Controls - Stock Traders Daily
Biohaven's troriluzole gains FDA priority review for SCA - MSN
Biohaven (NYSE:BHVN) Now Covered by Deutsche Bank Aktiengesellschaft - MarketBeat
Biohaven stock rises following FDA review and Deutsche Bank's buy rating - MSN
Biohaven (NYSE:BHVN) Shares Gap UpWhat's Next? - MarketBeat
WCM Investment Management LLC Takes Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Mississippi to receive$162.2K of $59.7M Settlement Over Alleged Biohaven Kickbacks - Vicksburg Daily News
Biohaven Ltd. Receives FDA Priority Review for Troriluzole, Boosting Investor Confidence - TipRanks
Why Biohaven Stock Triumphed on Tuesday - The Motley Fool
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
Biohaven, Ecolab, Firefly - TradingView
Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha
Biohaven stock rises following FDA review and Deutsche Bank’s buy rating - Investing.com Nigeria
Biohaven stock rises following FDA review and Deutsche Bank's buy rating By Investing.com - Investing.com South Africa
Biohaven Says FDA Grants Priority Review to Neurodegenerative Disorder Drug; Shares Rise - Marketscreener.com
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA - TipRanks
Why Biohaven Ltd. Shares Are Tumbling? - TipRanks
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire
Jennison Associates LLC Makes New $3.64 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
China Universal Asset Management Co. Ltd. Makes New $575,000 Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Kickback Case Settled For $59M - NewsBreak
SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision - TipRanks
Biohaven FY2025 EPS Forecast Decreased by Leerink Partnrs - MarketBeat
(BHVN) Technical Data - Stock Traders Daily
Leerink Partnrs Decreases Earnings Estimates for Biohaven - Defense World
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Nebraska joins in settling kickback allegations against Biohaven - norfolkneradio.com
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Multiple System Atrophy (MSA) Market 2025-2032 Business - openPR
Nebraska joins multi-state settlement against Biohaven Pharmaceutical for kickback allegations - NEWS CHANNEL NEBRASKA
Nebraska joins in settling kickback allegations against Biohaven Pharmaceutical Holding Company Ltd. - News Channel Nebraska
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):